RATIONALE: Dronabinol (Δ(9)tetrahydrocannabinol) is approved for HIV-related anorexia, yet, little is known about its effects in HIV-positive marijuana smokers. HIV-negative marijuana smokers require higher than recommended dronabinol doses to experience expected effects. OBJECTIVES: Employing a within-subjects, double-blind, placebo-controlled design, we assessed the effects of repeated high-dose dronabinol in HIV-positive marijuana smokers taking antiretroviral medication. METHODS:Participants (N = 7), who smoked marijuana 4.2 ± 2.3 days/week, resided in a residential laboratory for two 16-day stays, receiving dronabinol (10 mg QID) in one stay and placebo in the other. Efficacy was assessed with objectively verified food intake and body weight. Tolerability was measured with sleep, subjective, and cognitive assessments. For analyses, each inpatient stay was divided into two phases, days 1-8 and 9-16; we compared dronabinol's effects with placebo in each 8-day phase to investigate tolerance. RESULTS: Despite sustained increases in self-reported food cravings, dronabinol only increased caloric intake in the initial 8 days of dosing. Similarly, sleep quality was improved only in the first 8 days of dosing. Dronabinol's mood-enhancing effects were sustained across the 16-day inpatient stay. Dronabinol was well tolerated, causing few negative subjective or cognitive effects. CONCLUSIONS: In HIV-positive marijuana smokers, high dronabinol doses safely and effectively increased caloric intake. However, repeated high-dose dronabinol appeared to result in selective tolerance to these effects. These findings indicate that HIV-positive individuals who smoke marijuana may require higher dronabinol doses than are recommended by the FDA. Future research to establish optimal dosing regimens, and reduce the development of tolerance, is required.
RCT Entities:
RATIONALE: Dronabinol (Δ(9)tetrahydrocannabinol) is approved for HIV-related anorexia, yet, little is known about its effects in HIV-positive marijuana smokers. HIV-negative marijuana smokers require higher than recommended dronabinol doses to experience expected effects. OBJECTIVES: Employing a within-subjects, double-blind, placebo-controlled design, we assessed the effects of repeated high-dose dronabinol in HIV-positive marijuana smokers taking antiretroviral medication. METHODS:Participants (N = 7), who smoked marijuana 4.2 ± 2.3 days/week, resided in a residential laboratory for two 16-day stays, receiving dronabinol (10 mg QID) in one stay and placebo in the other. Efficacy was assessed with objectively verified food intake and body weight. Tolerability was measured with sleep, subjective, and cognitive assessments. For analyses, each inpatient stay was divided into two phases, days 1-8 and 9-16; we compared dronabinol's effects with placebo in each 8-day phase to investigate tolerance. RESULTS: Despite sustained increases in self-reported food cravings, dronabinol only increased caloric intake in the initial 8 days of dosing. Similarly, sleep quality was improved only in the first 8 days of dosing. Dronabinol's mood-enhancing effects were sustained across the 16-day inpatient stay. Dronabinol was well tolerated, causing few negative subjective or cognitive effects. CONCLUSIONS: In HIV-positive marijuana smokers, high dronabinol doses safely and effectively increased caloric intake. However, repeated high-dose dronabinol appeared to result in selective tolerance to these effects. These findings indicate that HIV-positive individuals who smoke marijuana may require higher dronabinol doses than are recommended by the FDA. Future research to establish optimal dosing regimens, and reduce the development of tolerance, is required.
Authors: D Robin Taylor; David M Fergusson; Barry J Milne; L John Horwood; Terrie E Moffitt; Malcolm R Sears; Richie Poulton Journal: Addiction Date: 2002-08 Impact factor: 6.526
Authors: Carl L Hart; Amie S Ward; Margaret Haney; Sandra D Comer; Richard W Foltin; Marian W Fischman Journal: Psychopharmacology (Berl) Date: 2002-09-14 Impact factor: 4.530
Authors: Carl L Hart; Margaret Haney; Amie S Ward; Marian W Fischman; Richard W Foltin Journal: Drug Alcohol Depend Date: 2002-08-01 Impact factor: 4.492
Authors: Jonathan W Lovelace; Alex Corches; Philip A Vieira; Alex S Hiroto; Ken Mackie; Edward Korzus Journal: Neuropharmacology Date: 2015-05-13 Impact factor: 5.250
Authors: Evan S Herrmann; Ziva D Cooper; Gillinder Bedi; Divya Ramesh; Stephanie C Reed; Sandra D Comer; Richard W Foltin; Margaret Haney Journal: Psychopharmacology (Berl) Date: 2016-04-16 Impact factor: 4.530
Authors: Laura M Campbell; Bin Tang; C Wei-Ming Watson; Michael Higgins; Mariana Cherner; Brook L Henry; Raeanne C Moore Journal: Cannabis Date: 2020-07-03
Authors: Margaret Haney; Ziva D Cooper; Gillinder Bedi; Suzanne K Vosburg; Sandra D Comer; Richard W Foltin Journal: Neuropsychopharmacology Date: 2013-02-26 Impact factor: 7.853
Authors: David A Gorelick; Robert S Goodwin; Eugene Schwilke; David M Schwope; William D Darwin; Deanna L Kelly; Robert P McMahon; Fang Liu; Catherine Ortemann-Renon; Denis Bonnet; Marilyn A Huestis Journal: J Anal Toxicol Date: 2012-10-16 Impact factor: 3.367